|
Market Closed -
Other stock markets
|
After hours 20:00:00 | |||
| 15.42 USD | +7.23% |
|
22.18 | +43.81% |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,436 | 10,512 | 10,021 | 8,956 | - | - |
| Change | - | 631.97% | -4.67% | -10.63% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 8,694 | 8,945 | 8,596 |
| Change | - | 631.97% | -9.69% | -8.41% | 2.88% | -3.9% |
| P/E | -2.62x | -58.1x | -12.2x | -13.6x | -13.7x | -28.1x |
| PBR | - | - | 20.7x | 160x | 2,308x | 27.9x |
| PEG | - | 0.8x | -0x | 0.7x | 20.15x | 0.5x |
| Capitalization / Revenue | - | - | - | 3,659x | 213x | 20.9x |
| EV / Revenue | - | - | - | 3,552x | 213x | 20.1x |
| EV / EBITDA | - | -96.9x | -11.7x | -16.5x | -18.3x | -35.4x |
| EV / EBIT | - | -58.8x | -11.7x | -13.5x | -13.1x | -19.2x |
| EV / FCF | - | -93.4x | -39.6x | -18x | -16.4x | -16.7x |
| FCF Yield | - | -1.07% | -2.52% | -5.54% | -6.1% | -6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.8472 | -0.8414 | -0.4103 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 2.448 | 42.03 | 427.7 |
| EBITDA 1 | - | -108.4 | -810.4 | -526.1 | -489.3 | -242.6 |
| EBIT 1 | - | -178.8 | -810.5 | -644.7 | -683.6 | -447.3 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -657.4 | -680.4 | -331.8 |
| Net Debt 1 | - | - | -528.6 | -261.7 | -11.05 | -360 |
| Reference price 2 | 2.05 | 14.25 | 13.00 | 11.54 | 11.54 | 11.54 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 776,163 | - | - |
| Announcement Date | 2/20/24 | 2/24/25 | 2/23/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.62x | 3552.08x | -16.52x | -.--% | 11.97B | |
| 35.79x | 9x | 27.97x | 0.05% | 58.73B | |
| 20.24x | 6.22x | 13.5x | 1.49% | 53.92B | |
| -19.35x | 4.94x | -8.63x | -.--% | 24.67B | |
| -42.26x | 14x | -40.82x | -.--% | 24.19B | |
| 23.43x | 4.62x | 11.99x | -.--% | 18.8B | |
| 24.57x | 4.85x | 16.08x | -.--% | 17.61B | |
| 48.53x | 19.97x | 52.67x | 0.06% | 16.25B | |
| 17.56x | 5.1x | 11.91x | -.--% | 14.04B | |
| -488.19x | 33.47x | -3731.69x | -.--% | 13.9B | |
| Average | -39.33x | 365.43x | -366.35x | 0.16% | 25.41B | |
| Weighted average by Cap. | -13.18x | 176.60x | -194.34x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
